Drugs / Avexitide
Avexitide
also known as
Exendin(9-39) · Ex-9 · exendin(9-39)amide · Ex9-39 · Avexitida · ex(9-39)NH2 · exendin(9-39)NH2 · Exendin-3 (9-39) amide
Trials 33
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT02823665 | Jul 2015 → Aug 2026 overdue | postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT01843881 | Mar 2012 → Sep 2013 | type 2 diabetes mellitus | Adrian Vella | Completed | No outcome recorded |
| Phase 0 | NCT01843855 | Jun 2011 → Jul 2013 | type 2 diabetes mellitus | Adrian Vella | Completed | No outcome recorded |
| Phase 0 | NCT00992901 | Oct 2009 → Aug 2026 overdue | hypoglycemia, postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 0 | NCT01803451 | Nov 2005 → Aug 2026 overdue | postgastrectomy syndrome | The University of Texas Health Science Center at San Antonio | Recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT04347252 | Sep 2019 → Apr 2021 | — | David D'Alessio, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT02550145 | Feb 2014 → Dec 2016 | hypoglycemia | Tracey McLaughlin | Terminated | No outcome recorded |
| Phase 1 | NCT01795144 | Jan 2014 → Mar 2017 | monogenic diabetes | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00551590 | Dec 2007 → Dec 2008 | type 2 diabetes mellitus | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT00393445 | Nov 2006 → May 2007 | hyperglycemia | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1/23 trials · 1 met primary | ||||||
| Phase 1/2 | NCT00835328 | Aug 2009 → Jan 2017 | congenital isolated hyperinsulinism | Diva De Leon | Terminated | No outcome recorded |
| Phase 1/2 | NCT00897676 | May 2009 → Aug 2016 | congenital isolated hyperinsulinism | Diva De Leon | Completed | No outcome recorded |
| Phase 1/2 | NCT00571324 | Aug 2007 → Dec 2014 | congenital isolated hyperinsulinism | Diva De Leon | Completed | Met primary |
| Phase 25 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT04652479 | Jun 2021 → Jun 2022 | hyperinsulinemic hypoglycemia | Dr. Tracey McLaughlin, MD | Completed | Met primary |
| Phase 2 | NCT03373435 | Mar 2018 → Jan 2019 | adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia | Eiger BioPharmaceuticals | Completed | Met primary |
| Phase 2 | NCT02771574 | May 2016 → Jun 2017 | postgastrectomy syndrome | Tracey McLaughlin | Completed | No outcome recorded |
| Phase 2 | NCT02697253 | Jan 2016 → Jul 2021 | obesity disorder | Icahn School of Medicine at Mount Sinai | Withdrawn | No outcome recorded |
| Phase 2 | NCT02170870 | Jun 2014 → Nov 2017 | diabetes mellitus, dyspepsia | Mayo Clinic | Completed | Missed primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06747468 | Apr 2025 → Mar 2026 overdue | postgastrectomy syndrome | Amylyx Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04459338 | Mar 2021 → Jun 2022 | — | Adrian Vella | Completed | Met primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT02844907 | Jul 2018 → Dec 2021 | — | VA Office of Research and Development | Terminated | No outcome recorded Stop: Business |
| Phase 4 | NCT03101930 | May 2017 → Jun 2021 | obesity disorder, prediabetes syndrome | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01701973 | Jan 2013 → May 2017 | obesity disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase not applicable9 trials · 1 met primary | ||||||
| — | NCT06872060 | Jun 2026 → Nov 2027 expected | kidney disorder | Bispebjerg Hospital | Not yet recruiting | No outcome recorded |
| — | NCT03241303 | Aug 2017 → Jan 2018 | glucose metabolism disease | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT03246451 | Jul → Dec 2017 | glucose metabolism disease | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT02746757 | May 2015 → Dec 2017 | — | Karolinska Institutet | Completed | No outcome recorded |
| — | NCT02336659 | Apr 2014 → May 2016 | morbid obesity | Hvidovre University Hospital | Completed | No outcome recorded |
| — | NCT01729299 | Apr 2013 → Apr 2014 | diabetes mellitus | David Dalessio | Unknown | No outcome recorded |
| — | NCT01363609 | Oct 2011 → Jan 2015 | obesity disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | Met primary |
| — | NCT01281228 | Sep 2011 → Oct 2013 | obesity disorder, type 2 diabetes mellitus | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01162499 | Apr 2010 → Dec 2014 | hypoglycemia | Diva De Leon | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07582874 | — | postgastrectomy syndrome | Amylyx Pharmaceuticals Inc. | Available | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 1 | NCT07806695 Background | Sep 2026 → Mar 2030 expected | gestational diabetes | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1 | NCT02996812 Comparator | Apr 2015 → Aug 2016 | hyperinsulinemic hypoglycemia | Tracey McLaughlin | Completed | No outcome recorded |
| Phase 1 | NCT02128581 Comparator | May 2014 → Mar 2016 | diabetes mellitus, obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01218633 Comparator | May 2011 → Jul 2012 | endocrine pancreas disorder | Adrian Vella | Completed | No outcome recorded |
| Phase 1 | NCT01449019 Comparator | Dec 2006 → Aug 2007 | type 2 diabetes mellitus | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT00980083 Comparator | Oct 2004 → Jul 2005 | — | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT00468091 Comparator | Feb 1999 → Sep 2000 | endocrine pancreas disorder, intestinal motility disease | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 2 | NCT06972407 Comparator | Oct 2026 → Dec 2028 expected | type 2 diabetes mellitus | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06967558 Comparator | Nov 2025 → Oct 2027 expected | prediabetes syndrome | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT02762708 Comparator | Mar 2016 → Jan 2018 | obesity disorder, type 2 diabetes mellitus | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT04466566 Comparator | Oct 2022 → Sep 2025 | — | Adrian Vella | Completed | No outcome recorded |
| Phase 3 | NCT04466618 Comparator | Apr 2021 → Dec 2022 | type 2 diabetes mellitus | Adrian Vella | Completed | No outcome recorded |
| Phase 4 | NCT02639130 Comparator | Feb 2008 → Jan 2010 | type 2 diabetes mellitus | Diabeteszentrum Bad Lauterberg im Harz | Completed | No outcome recorded |
| — | NCT07373236 Comparator | Jan → Apr 2026 | type 1 diabetes mellitus | Asger Lund, MD | Completed | No outcome recorded |
| — | NCT02779075 Comparator | Jun 2016 → Jul 2019 | obesity disorder | Mayo Clinic | Completed | No outcome recorded |
| — | NCT01152333 Comparator | Jul 2010 → Jul 2016 | obesity disorder | University of Washington | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 59 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Avexitide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06747468 ↗ |
| Known as | Avexitida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297949 ↗ |
| Known as | ex(9-39)NH2 | “In vitro, the nonmammalian peptide, exendin(9-39)amide [ex(9-39)NH2], is a specific and competitive antagonist of GLP-1.” PMID 9525985 ↗ Apr 1998 |
| Known as | Ex-9 | “continuous infusion of the GLP-1 receptor antagonist exendin (9-39) (Ex-9)” PMID 24315990 ↗ Dec 20135“Exendin 9-39 (Ex9) is a specific GLP-1 receptor antagonist” NCT02996812 ↗ “GLP-1 receptor (GLP-1R) antagonist Exendin(9-39) (Ex-9).” NCT01729299 ↗ “GLP-1 receptor antagonist exendin(9-39) (Ex9)” PMID 30065032 ↗ Jul 2018 “GLP-1 antagonist Exendin-[9-39] (Ex-9)” PMID 25049134 ↗ Jul 2014 “Exendin (9-39) (Ex-9)” PMID 27975209 ↗ Dec 2016 |
| Known as | Ex9-39 | “Using the specific GLP-1 receptor antagonist exendin(9-39)amide (Ex(9-39)) the investigators recently showed that GLP-1 released during intestinal meal perfusion acts as an...” NCT00980083 ↗2“Effects of the GLP-1 receptor antagonist exendin 9-39 (Ex9-39) and placebo were assessed in 10 women before and after RYGB.” PMID 29025878 ↗ Nov 2017 “the GLP-1 antagonist exendin 9-39 (Ex 9-39).” NCT02746757 ↗ |
| Known as | Exendin(9-39) | “On one occasion, exendin 9-39, a competitive antagonist of the GLP-1 Receptor (GLP1R), was infused, while on the other, saline was infused.” PMID 37751301 ↗ Nov 202347“Effects of the GLP-1 receptor antagonist exendin 9-39 (Ex9-39) and placebo were assessed in 10 women before and after RYGB.” PMID 29025878 ↗ Nov 2017 “plus a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-¹·min-¹), given intravenously from -30 to 60 minutes” NCT06872060 ↗ “concurrently exendin-(9-39) will be infused at 750 pmol/kg/min, also for the remaining 180 minutes.” NCT04347252 ↗ “Exendin-(9,39) is a competitive antagonist of glucagon-like peptide-1 (GLP-1) at its receptor.” PMID 23545708 ↗ Apr 2013 “Avexitide (exendin 9-39) is a competitive antagonist of GLP-1 at its receptor” NCT04652479 ↗ “continuous infusion of the GLP-1 receptor antagonist exendin (9-39) (Ex-9)” PMID 24315990 ↗ Dec 2013 “Exendin 9-39 (Ex9) is a specific GLP-1 receptor antagonist” NCT02996812 ↗ “GLP-1 receptor (GLP-1R) antagonist Exendin(9-39) (Ex-9).” NCT01729299 ↗ |
| Known as | exendin(9-39)amide | “Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.” PMID 9525985 ↗ Apr 1998 |
| Known as | exendin(9-39)NH2 | “Using the glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) antagonist exendin(9-39)NH2, we tested the hypothesis that postprandial GLP-1-mediated effects contribute to the...” PMID 39049802 ↗ Aug 2024 |
| Known as | Exendin-3 (9-39) amide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297949 ↗ |
| Action | Inhibit | “In vitro, the nonmammalian peptide, exendin(9-39)amide [ex(9-39)NH2], is a specific and competitive antagonist of GLP-1.” PMID 9525985 ↗ Apr 1998 |
| Modality | Peptide | “In vitro, the nonmammalian peptide, exendin(9-39)amide [ex(9-39)NH2], is a specific and competitive antagonist of GLP-1.” PMID 9525985 ↗ Apr 1998 |
| Route | Intravenous | “intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min” NCT00393445 ↗ |
| Target | GLP1R | “glucagon-like peptide 1 (GLP-1) receptor antagonist” PMID 22721966 ↗ Jun 2012 |